Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00014638. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Estrogen can stimulate the growth of cancer cells. Letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase IV trial to study the effectiveness of letrozole in treating postmenopausal women who have metastatic breast cancer that has been previously treated with tamoxifen.
Study identification
- NCT ID
- NCT00014638
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2000
- Primary completion
- Feb 28, 2002
- Completion
- Feb 28, 2002
- Last update posted
- Feb 20, 2013
2001 – 2002
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Long Beach Memorial Breast Center | Long Beach | California | 90806 | — |
| Cancer Research Network, Inc. | Hollywood | Florida | 33020 | — |
| Oncology-Hematology Group of South Florida | Miami | Florida | 33176 | — |
| Pharm Research | Pinecrest | Florida | 33156 | — |
| Cancer Research Network Inc. | Plantation | Florida | 33324 | — |
| Good Samaritan Medical Center | West Palm Beach | Florida | 33401 | — |
| Illinois Oncology, Ltd. | Belleville | Illinois | 62221 | — |
| Joliet Oncology/Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Memorial Medical Center | Springfield | Illinois | 62781 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Southwest Oncology Association | Lafayette | Louisiana | 70503 | — |
| New Mexico Oncology-Hematology | Albuquerque | New Mexico | 87109 | — |
| Albert Einstein Comprehensive Cancer Center | The Bronx | New York | 10461 | — |
| Oncology Partnership Network | Cincinnati | Ohio | 45238 | — |
| Memphis Cancer Center | Memphis | Tennessee | 38119 | — |
| Dial Research Associates, Inc. | Nashville | Tennessee | 37205 | — |
| Center for Oncology Research and Treatment, Medical City Hospital | Dallas | Texas | 75230 | — |
| Intermountain Hematology/Oncology Associates, Inc. | Salt Lake City | Utah | 84124 | — |
| Cascade Cancer Center | Kirkland | Washington | 98034-3013 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00014638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2013 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00014638 live on ClinicalTrials.gov.